Wikipedia -WSS

Wikipedia

author：explore 2025-10-02 18:48:40 - browse：89586

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Fight over Supreme Court dialysis ruling puts kidney patients at risk

hotspot

WSS

The most pressing bird flu mysteries scientists want answered

ASCO Daily Recap: CAR

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

hotspot

Wikipedia

Wikipedia

ChatGPT in medicine: STAT answers readers' burning questions

A new initiative will help leaders fight the next pandemic

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Medical records are filled with copy

Anthos stroke drug appears safer than common blood thinner

In Memoriam: Notable people who died in 2023

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Novavax promises a turnaround & Lilly roils the obesity market

Data don't support strong claims for Covid

focus

FTC loses bid to block Novant's North Carolina hospital merger

Hospitals look to new technology to keep health care workers safe

Does good food count as health care? Study aims to find out

Does good food count as health care? Study aims to find out

In key trial, Verve's treatment lowers cholesterol levels in patients

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

focus

hotspot

hotspot

knowledge